Pharmaceutical Research

, Volume 17, Issue 12, pp 1468–1474 | Cite as

Design and In Vivo Evaluation of An Oral Delivery System for Insulin

  • Michaela K. Marschütz
  • Paolo Caliceti
  • Andreas Bernkop-Schnürch


Purpose. To develop an oral controlled release system for insulin.

Methods. The polymer-inhibitor conjugates carboxymethylcellulose (CMC)-Bowman-Birk inhibitor and CMC-elastatinal were homo- genized with polycarbophil-cysteine conjugate, insulin, and mannitol, compressed to 2 mg microtablets and enteric coated with a polymethacrylate. The protective effect of this delivery system for insulin towards enzymatic degradation, as well as the release profile, was evaluated in vitro. In addition, the effect of the dosage form on glucose levels of diabetic mice was determined.

Results. Tablets containing the CMC-inhibitor conjugates showed a strong protective effect for insulin. Whereas 91.6 ± 7.4% (mean ± SD, n = 3) of insulin in the dosage form without the inhibitor conjugates has been degraded within 3 h of incubation in an artificial intestinal fluid containing physiological concentrations of trypsin, chymotrypsin, and elastase, 49.7 ± 5.5% (mean ± SD, n = 3) of insulin remained stable in the delivery system containing the polymer-inhibitor conjugates. Additionally, polycarbophil-cysteine (PCP-Cys) provides high cohesiveness of the dosage form, due to the formation of inter- as well as intramolecular disulfide bonds within the polymer matrix. According to this, a controlled release of insulin could be achieved over a time period of 10 h. Furthermore, in vivo studies in diabetic mice showed a decrease in basal glucose levels of 20% to 40% during a time period of 80 h.

Conclusions. Mucoadhesive polymer-inhibitor conjugates might represent a promising excipient in delivery systems for oral (poly)peptide delivery.

controlled release enzyme inhibitors insulin degradation mucoadhesive polymers oral insulin delivery protective effect serine proteases thiolated polymers 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    G. Gwinup, A. N. Elias, and N. D. Vaziri. A case for oral insulin therapy in the prevention of diabetic micro-and macroangiopathy. Int. J. Artif. Organs 13:393–395 (1990).Google Scholar
  2. 2.
    F. P. Kennedy. Recent developments in insulin delivery techniques: current status and future potential. Drugs 42:213–227 (1991).Google Scholar
  3. 3.
    Z. Shao, Y. Li, R. Krishnamoorthy, T. Chermak, and A. K. Mitra. Differential effects of anionic, cationic, non-ionic and physiologic surfactants on the dissociation, chymotryptic degradation, and enteral absorption of insulin hexamers. Pharm. Res. 10:243–250 (1993).Google Scholar
  4. 4.
    T. Nishihata, J. H. Tytting, A. Kamada, and T. Higuchi. Enhanced intestinal absorption of insulin in the presence of sodium 5-methoxysalicylate. Diabetes 30:1065–1067 (1981).Google Scholar
  5. 5.
    M. Morishita, I. Morishita, K. Takayama, M. Yoshiharu, and T. Nagai. Site-dependent effect of aprotinin, sodium caprate, Na2EDTA, and sodium glycocholate on intestinal absorption of insulin. Biol. Pharm. Bull. 16:68–72 (1993).Google Scholar
  6. 6.
    E. Ziv, O. Lior, and M. Kidron. Absorption of protein via the intestinal wall. Biochem. Pharmacol. 36:1035–1039 (1987).Google Scholar
  7. 7.
    S. Fujii, T. Yokoyama, K. Ikegaya, F. Sata, and N. Yokoo. Promoting effect of the new chymotrypsin inhibitor KD-488 on the intestinal absorption of insulin in rats and dogs. J. Pharm. Pharmacol. 37:545–549 (1985).Google Scholar
  8. 8.
    A. Bernkop-Schnürch, G. H. Schwarz, and M. Kratzel. Modified mucoadhesive polymers for the peroral administration of mainly elastase degradable therapeutic (poly)peptides. J. Controlled Release 47:113–121 (1997).Google Scholar
  9. 9.
    A. Bernkop-Schnürch, R. Kirchmayer, and M. Kratzel. Synthesis, development and in vitro evaluation of drug delivery systems with protective effect against degradation by pepsin. J. Drug Targ. 7:55–63 (1999).Google Scholar
  10. 10.
    M. K. Marschütz and A. Bernkop-Schnürch. Oral peptide drug delivery: Polymer-inhibitor conjugates protecting insulin from enzymatic degradation in vitro. Biomaterials 21:1499–1507 (2000).Google Scholar
  11. 11.
    A. Bernkop-Schnürch, S. Scholler, and R.G. Biebel. Development of controlled drug release systems based on polymercysteine conjugates. J. Controlled Release 66:39–48 (2000).Google Scholar
  12. 12.
    A. Bernkop-Schnürch, V. Schwarz, and S. Steininger. Polymers with thiol groups: A new generation of mucoadhesive polymers? Pharm. Res. 16:876–881 (1999).Google Scholar
  13. 13.
    A. Bernkop-Schnürch and S. Steininger. Synthesis and characterization of mucoadhesive thiolated polymers. Int. J. Pharm. 194: 239–247 (2000).Google Scholar
  14. 14.
    A. Bernkop-Schnürch. The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins. J. Controlled Release 52:1–16 (1998).Google Scholar
  15. 15.
    H. Tozaki, J. Komoike, Ch. Tada, T. Maruyama, A. Terabe, T. Suzuki, A. Yamamoto, and S. Muranishi. Chitosan capsules for colon-specific drug delivery: Improvement of insulin absorption from the rat colon. J. Pharm. Sci. 86:1016–1021 (1997).Google Scholar
  16. 16.
    J. F. Woodley. Enzymatic barriers for GI peptide and protein delivery. Crit. Rev. Ther. Drug 11:61–95 (1994).Google Scholar
  17. 17.
    J. L. Cleland, M. F. Powell, and S. J. Shire. The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. Crit. Rev. Ther. Drug 10:307–377 (1993).Google Scholar
  18. 18.
    M. Baudys, T. Uchio, D. Mix, D. Wilson, and S. Wan Kim. Physical stabilization of insulin glycosylation. J. Pharm. Sci. 84:28–33 (1995).Google Scholar
  19. 19.
    R. A. Pullen, D. G. Lindsay, S. P. Wood, I. J. Tickle, T. L. Blundell, A. Wollmer, G. Krail, D. Brandenburg, H. Zahn, J. Gliemann, and S. Glameltoft. Receptor-binding region of insulin. Nature 259:369–373 (1976).Google Scholar
  20. 20.
    A. Bernkop-Schnürch and S. Thaler. Polycarbophil-cysteine conjugates as platforms for oral (poly)peptide delivery systems. J. Pharm. Sci. 89:901–909 (2000).Google Scholar
  21. 21.
    C.-M. Lehr. Bioadhesion technologies for the delivery of peptide and protein drugs to the gastrointestinal tract. Crit. Rev. Ther. Drug 11:119–160 (1994).Google Scholar
  22. 22.
    H. Takeuchi, H. Yamamoto, T. Niwa, T. Hino, and Y. Kawashima. Enteral absorption of insulin in rats from mucoadhesive chitosan-coated liposomes. Pharm. Res. 13:896–901 (1996).Google Scholar
  23. 23.
    Z. Chap, T. Ishida, J. Chou, C. J. Hartley, R. M. Lewis, M. Entman, and J. B. Field. Effect of metabolic clearance rate and hepatic extraction of insulin on hepatic and peripheral contributions to hypoglycemia. J. Clin. Invest. 76:2222–2234 (1985).Google Scholar

Copyright information

© Plenum Publishing Corporation 2000

Authors and Affiliations

  • Michaela K. Marschütz
    • 1
  • Paolo Caliceti
    • 2
  • Andreas Bernkop-Schnürch
    • 3
  1. 1.Center of Pharmacy, Institute of Pharmaceutical Technology and BiopharmaceuticsUniversity of ViennaViennaAustria
  2. 2.Department of Pharmaceutical SciencesUniversity of PaduaPadovaItaly
  3. 3.Center of Pharmacy, Institute of Pharmaceutical Technology and BiopharmaceuticsUniversity of ViennaViennaAustria

Personalised recommendations